Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as...

Full description

Bibliographic Details
Main Authors: Jakub Radocha, Niels W. C. J. van de Donk, Katja Weisel
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/7/1571